There have been recent concerns raised about the hospital care of patients with diabetes insipidus and the morbidity and mortality associated with delay or omission of administration of desmopressin. This is a review of diabetes insipidus and desmopressin with a practical guide to management of these complex patients for the general paediatrician or intensive care physician caring for these children out of hours when access to specialist endocrinology may not be available.
Introduction
In February this year NHS England released a patient safety alert highlighting the associated mortality and morbidity when desmopressin is omitted in individuals with cranial diabetes insipidus 1 . Over a seven-year period the UK National Reporting and Learning System had identified 76 near misses, 56 dosing errors leading to harm and four cases where desmopressin omission has resulted in severe dehydration and death 1 
. Gleeson et al,
concerned about the care of adult patients with diabetes insipidus (DI) when admitted to hospital, recently reported a retrospective audit in which desmopressin was missed or delayed in 88% of admissions, in two thirds of cases because medication was unavailable 2 .
Both publications raise awareness of the risks and call for improved education, easier access to desmopressin in the inpatient setting and heightened pharmacovigilance; using increasingly popular e-prescribing to flag patients on desmopressin and alert endocrinologists to their admission 1, 2 .
To our knowledge there are no comparable data available in paediatrics, but the risks of children with DI not receiving the care they require is a concern. Paediatricians increasingly face complex children, on multiple, often unfamiliar, drugs, requiring management from generalists or intensivists when admitted out of hours who may not have immediate access to specialist paediatric endocrinology. To compound the issue paediatric staff are often familiar with the more common indication for desmopressin, enuresis, and therefore may not identify it as a critical medication, increasing the risk of omission. These patients are often on concomitant glucocorticoid replacement, which may complicate matters further.
It is therefore timely to review situations when the generalist or intensivist may come into contact with patients with DI and to summarise management strategies and pitfalls to avoid.
What is Diabetes Insipidus?
Diabetes insipidus (DI) describes polyuria and polydipsia occurring due to an inability to concentrate urine. Central or cranial DI occurs when there is a lack of arginine vasopressin (AVP) (interchangeably referred to as anti-diuretic hormone (ADH), vasopressin or argipressin) and nephrogenic DI when the kidneys fail to respond to the AVP secreted by the posterior pituitary gland. AVP acts on receptors located in the collecting duct of the kidney, enabling aquaporin channels to allow water reabsorption from the duct lumen into the cells. DI is rare, with an estimated prevalence of 1 in 25,000 3 . In children cranial DI is the cause in more than 90% cases 4 . There are many causes from abnormalities of development to acquired forms (table 1) This may present as new-onset enuresis in older children with a commensurate rise in serum sodium and plasma osmolality, leading to osmoreceptor activation and a compensatory polydipsia. When children have access to fluids, serum sodium can be kept within 2% of normal levels 5 .
The diagnosis of DI can be challenging and distinguishing from other causes, most notably habitual drinking in children, difficult. A high serum osmolality (>300 mOsm/kg) in the presence of inappropriately dilute urine (<300 mOsm/kg or urine/plasma osmolality ratio <1) from paired early morning samples is diagnostic. Hypernatraemia (sodium >145 mmol/l) may or may not be present. However, in many cases of DI there is a partial release of AVP during periods of dehydration, thus a water deprivation test, carried out in a specialist centre, may be required to reach a definitive diagnosis. The initial diagnosis, differentiation and subsequent out-patient management of DI, particularly infants, has been covered comprehensively elsewhere [3] [4] [5] [6] . Young patients requiring small doses may not be suitable for the nasal spray, which cannot deliver less than 0.1ml (10 micrograms). It is important to note that the formulations are not easily interchangeable, with exact information as to the relative bioavailabilities hard to come by 9 . An approximate conversion guide for children aged 12 and above, derived from multiple sources, is provided in table 3. There is significant variation in published bioavailabilities, particularly for oral and nasal formulations, and therefore these are not routinely used in clinical practice. Clinical monitoring of effect and dose adjustment is essential for children of all ages and we suggest early involvement of a paediatric pharmacist. Intravenous desmopressin (aqueous pitressin) is usually reserved for the paediatric intensive care setting where its very short half-life allows for greater flexibility in fluid management. Historically cranial DI has been treated with chlorpropamide, carbamazepine and clofibrate but synthetic AVP has now rendered the use of these outdated 10, 11 . 
Desmopressin

In-patient management of a child with diabetes insipidus
Special considerations
Concomitant administration with hydrocortisone
It is important to ascertain whether a patient on desmopressin is also on steroid replacement medication 2 . Cortisol is required for the excretion of free water. Cortisol insufficiency can therefore lead to hyponatraemia, which will be exacerbated by the administration of desmopressin. Children with pituitary dysfunction are often taking hydrocortisone and desmopressin concomitantly, and when unwell, hydrocortisone should be increased to match endogenous cortisol requirement. Unwell children with anterior and posterior pituitary dysfunction should increase their dose of hydrocortisone and have serum electrolytes checked before further administration of desmopressin to prevent dilutional hyponatraemia 12 . Children should be allowed to drink freely, as the thirst stimulus will serve to regulate serum sodium whilst off desmopressin. In addition, when steroids have been increased ensure that the subsequent diuresis is not secondary to hyperglycaemia.
Overdose with desmopressin
Overdose with desmopressin in patients with DI is rare, and should be managed by a specialist. Symptomatic dilutional hyponatremia is the main complication but in rare cases, cerebral oedema may result from intravascular fluid shifts. No further desmopressin should be given. If investigations indicate hyponatraemia with low serum osmolality paired with high urine osmolality and oliguria, then this is one of the only circumstances where fluid restriction may be necessary. In severe hyponatraemia hypertonic saline infusion may be required to carefully normalise serum sodium.
Adipsic DI
Patients with complex midline CNS abnormalities may have defective AVP osmoregulation leading to low or no thirst response to plasma hypertonicity. Up to 20% of patients following pituitary surgery are reported to have thirst dysregulation 13, 14 . Fluid management in the adipsic DI patient is challenging. Monitoring admitted patients with established adipsic DI should follow exactly the same process as those with an intact thirst mechanism but personalised fixed fluid regimes are required to ensure they receive the appropriate volume of fluid in relation to their dose of desmopressin.
Summary
Whilst the initial management of patients with established DI outside specialist centres may appear both daunting and challenging, adhering to simple key principles will ensure the patient remains safe. Ensure that all staff are aware that the patient has DI and understand that strict fluid monitoring and management will ensure stability. Patients with DI should never be fluid restricted, desmopressin should not be omitted or delayed (other than when glucocorticoid doses have been increased) and patients should not self-administer desmopressin. Desmopressin should also be regularly available out of hours to avoid administration delays. A paediatric endocrinologist should be contacted as soon as possible after admission. Given the potential risk of morbidity and mortality as a result of failure to adhere to simple principles, in particular with out of hours and unplanned admissions, we recommend that a hospital alert system for patients with DI is established in line with the recommendations from NHS England 1, 2 .
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Key messages (textbox):
 Never fluid restrict a patient with diabetes insipidus.
 Desmopressin doses are highly individual and should be monitored by clinical effect.
 The doses of the different formulations of desmopressin are not interchangeable.
T the bioavailabilities do not support this and we recommend seeking pharmacy or endocrine advice when converting a patient on desmopressin to a different formulation.
 Strict fluid balance, and regular serum electrolyte, osmolality and urine osmolality monitoring are needed to ensure safe inpatient care of patients with DI. 
Route of administration
